Exclusive Summary

• Holds US-FDA GMP certification and US ANDA approval, enabling direct distribution in the US and allowing accelerated registration in emerging markets (e.g., LATAM, ASEAN) via the reliance pathway.
• Offers a complete strength portfolio of 25mg, 50mg, and 100mg, perfectly satisfying dose adjustment requirements for type 2 diabetes patients with varying degrees of renal impairment.
• Maximizes the strategic window of Januvia's global patent expirations, offering highly competitive pricing backed by China's efficient supply chain to rapidly capture generic substitution shares.
• Addresses the massive demand of over 537 million diabetics globally, delivering an ADA/EASD recommended standard-of-care drug known for cardiovascular safety and zero associated hypoglycemia risk.